
## New Systematic Naming for Synthetic Cannabinoid "MDA-19" and Its Related Analogues: BZO-HEXOXIZID, 5F-BZO-POXIZID, and BZO-POXIZID

**Purpose:** Cayman Chemical and NPS Discovery at the Center for Forensic Science Research and Education (CFSRE) have developed new, more appropriate names to address the newly emergent "MDA-19" and its related analogues following the systematic convention typically used for synthetic cannabinoid nomenclature.

Background: Synthetic cannabinoids represent a vastly diverse sub-class of novel psychoactive substances (NPS). The turnover of this sub-class is largely linked to drug scheduling actions and, like other sub-classes of NPS, new drugs were historically produced via slight tweaks to the molecular structure. In May 2021, China announced new legislation to control synthetic cannabinoids as a class using commonly encountered structural backbones. This has resulted in the emergence of new generations of synthetic cannabinoids with core components that were previously unencountered and/or not well characterized. An example is "MDA-19" and its related analogues. "MDA-19" is a CB<sub>2</sub> agonist and was studied, like many synthetic cannabinoids, under legitimate research for pharmaceutical purposes. Similar to JWH-018 and other early synthetic cannabinoids, naming conventions utilizing the initials of a researcher or organization are not ideal and may be misleading (e.g., the abbreviation "MDA" is also used for the stimulant drug methylenedioxyamphetamine). A well-accepted systematic naming convention exists for synthetic cannabinoids and should be applied, where appropriate, to avoid any confusion or mischaracterization.









BZO-HEXOXIZID	BZO-POXIZID	5F-BZO-POXIZID
		ON NON THE PROPERTY OF THE PRO
(Z)-N'-(1- <b>HEX</b> yl-2- <b>OX</b> o <b>I</b> ndolin-3-ylidene) <b>B</b> en <b>ZO</b> hydra <b>ZID</b> e	(Z)-N'-(1-Pentyl-2-OXoIndolin-3-ylidene)BenZOhydraZIDe	(Z)-N'-(1-(5-FluoroPentyl-2- OXoIndolin-3-ylidene) BenZOhydraZIDe
Name: BZO-HEXOXIZID	Name: BZO-POXIZID	Name: <b>5F-BZO-POXIZID</b>
Synonyms: MDA-19, MDA19, MDA 19	Synonyms: 5C-MDA-19, MDA-19 pentyl analogue	Synonyms: 5F-MDA-19, MDA-19 5-fluoropentyl analogue

## Acknowledgements:

This report was prepared by Robert M. Schelkun, MS; Alex J. Krotulski, PhD; Donna M. Iula, PhD; and Barry K. Logan, PhD, F-ABFT. Funding for NPS Discovery was received in part from the National Institute of Justice (NIJ) of the U.S. Department of Justice (DOJ) (Award Number 2020-DQ-BX-0007). The opinions, findings, and conclusions or recommendations expressed in this publication are those of the authors and do not necessarily reflect those of the Department of Justice.

## References and Related Articles:

- Attala MN, Daiz P. (2009) Patent WO2009012227A1. Hydrazone Modulators of Cannabinoid Receptors. <a href="https://patents.google.com/patent/US20180200225A1/en">https://patents.google.com/patent/US20180200225A1/en</a>
- Xu JJ, Diaz P, Astruc-Diaz F, Craig S, Munoz E, Naguib M. (2010) Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain. Anesthesia and Analgesia. 111, 99–109. <a href="https://pubmed.ncbi.nlm.nih.gov/20522703/">https://pubmed.ncbi.nlm.nih.gov/20522703/</a>
   Diaz P, Xu J, Astruc-Diaz F, Pan H, Brown DL, Naguib M. (2008) Design and Synthesis of a Novel Series of N-Alkyl Isatin Acylhydrazone Derivatives that Act as Selective Cannabinoid Receptor 2. Agonists for the Treatment of Neuropathic Pain. J. Med. Chem. 2008, 51, 4932–4947. <a href="https://pubs.acs.org/doi/10.1021/jm8002203">https://pubs.acs.org/doi/10.1021/jm8002203</a>
- Diaz P, Phatak SS, Xu J, Astruc-Diaz F, Cavasotto CN, and Naguib M. (2009) 6-Methoxy-N-alkyl Isatin Acylhydrazone Derivatives as a Novel Series of Potent Selective Cannabinoid Receptor 2 Inverse Agonists: Design, Synthesis, and Binding Mode Prediction. J. Med. Chem. 52, 433-444. <a href="https://pubs.acs.org/doi/10.1021/im801353p">https://pubs.acs.org/doi/10.1021/im801353p</a>
- Uchiyama N, Matsuda S, Wakana D, Kikura-Hanajiri R, Goda Y. (2013) New cannabimimetic indazole derivatives, N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-11-indazole-3-carboxamide (AB-FINACA) and N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA) identified as designer drugs in illegal products. Forensic Toxicology. 31, 93–100. <a href="https://link.springer.com/article/10.1007/s11419-012-0711-4">https://link.springer.com/article/10.1007/s11419-012-0711-4</a>